MERS-CoV

Middle East respiratory syndrome coronavirus (MERS-CoV) is an emerging zoonotic coronavirus. First identified in 2012, MERS-CoV has caused over 2460 infections and a fatality rate of about 35% in humans. Similar to severe acute respiratory syndrome coronavirus (SARS-CoV), MERS-CoV likely originated...

Full description

Saved in:
Bibliographic Details
Main Author: Du, Lanying (auth)
Other Authors: Li, Fang (auth)
Format: Electronic Book Chapter
Language:English
Published: MDPI - Multidisciplinary Digital Publishing Institute 2019
Subjects:
Online Access:DOAB: download the publication
DOAB: description of the publication
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000naaaa2200000uu 4500
001 doab_20_500_12854_53201
005 20210211
003 oapen
006 m o d
007 cr|mn|---annan
008 20210211s2019 xx |||||o ||| 0|eng d
020 |a books978-3-03921-851-6 
020 |a 9783039218509 
020 |a 9783039218516 
040 |a oapen  |c oapen 
024 7 |a 10.3390/books978-3-03921-851-6  |c doi 
041 0 |a eng 
042 |a dc 
072 7 |a PS  |2 bicssc 
100 1 |a Du, Lanying  |4 auth 
700 1 |a Li, Fang  |4 auth 
245 1 0 |a MERS-CoV 
260 |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2019 
300 |a 1 electronic resource (274 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
506 0 |a Open Access  |2 star  |f Unrestricted online access 
520 |a Middle East respiratory syndrome coronavirus (MERS-CoV) is an emerging zoonotic coronavirus. First identified in 2012, MERS-CoV has caused over 2460 infections and a fatality rate of about 35% in humans. Similar to severe acute respiratory syndrome coronavirus (SARS-CoV), MERS-CoV likely originated from bats; however, different from SARS-CoV, which potentially utilized palm civets as its intermediate hosts, MERS-CoV likely transmits to humans through dromedary camels. Animal models, such as humanized mice and nonhuman primates, have been developed for studying MERS-CoV infection. Currently, there are no vaccines and therapeutics approved for the prevention and treatment of MERS-CoV infection, although a number of them have been developed preclinically or tested clinically. This book covers one editorial and 16 articles (including seven review articles and nine original research papers) written by researchers working in the field of MERS-CoV. It describes the following three main aspects: (1) MERS-CoV epidemiology, transmission, and pathogenesis; (2) current progress on MERS-CoV animal models, vaccines, and therapeutics; and (3) challenges and future prospects for MERS-CoV research. Overall, this book will help researchers in the MERS-CoV field to further advance their work on the virus. It also has important implications for other coronaviruses as well as viruses outside the coronavirus family with pandemic potentials. 
540 |a Creative Commons  |f https://creativecommons.org/licenses/by-nc-nd/4.0/  |2 cc  |4 https://creativecommons.org/licenses/by-nc-nd/4.0/ 
546 |a English 
650 7 |a Biology, life sciences  |2 bicssc 
653 |a cell-cell fusion 
653 |a hDPP4 
653 |a n/a 
653 |a therapeutics 
653 |a animal models 
653 |a HCoV-229E 
653 |a Drivers 
653 |a camels 
653 |a rabbits 
653 |a SARS-CoV 
653 |a MERS-CoV 
653 |a MVA vaccine 
653 |a transmission 
653 |a RBD 
653 |a MERS-CoV nucleocapsid protein 
653 |a complement 
653 |a animal model 
653 |a pseudotyped virus 
653 |a combination 
653 |a MERS-coronavirus 
653 |a peptide 
653 |a mouse model 
653 |a spike protein 
653 |a receptor-binding domain 
653 |a prevention and treatment 
653 |a coronaviruses 
653 |a coronavirus spike glycoprotein 
653 |a therapeutic antibodies 
653 |a vaccine platforms 
653 |a mutation 
653 |a severe acute respiratory syndrome coronavirus 
653 |a pathogenesis 
653 |a fusion inhibitor 
653 |a Coronavirus 
653 |a murine CD8+ T cell epitope 
653 |a lipidomics 
653 |a authentic virus 
653 |a correlates of immunity 
653 |a vaccines 
653 |a neutralizing monoclonal antibodies 
653 |a Middle East respiratory syndrome coronavirus 
653 |a small-molecule inhibitor 
653 |a Middle East Respiratory Syndrome Virus 
653 |a DPP4 
653 |a pyroptosis 
653 |a cross-neutralization 
653 |a inflammation 
653 |a Qatar 
653 |a spike proteins 
653 |a One Health 
653 |a HKU4 
653 |a nanobodies 
653 |a mechanism of action 
653 |a neutralizing antibody 
653 |a host factors 
653 |a UHPLC-MS 
856 4 0 |a www.oapen.org  |u https://mdpi.com/books/pdfview/book/1893  |7 0  |z DOAB: download the publication 
856 4 0 |a www.oapen.org  |u https://directory.doabooks.org/handle/20.500.12854/53201  |7 0  |z DOAB: description of the publication